TERN-501

TERN-501
Legal status
Legal status	Investigational;
Identifiers
	IUPAC name N-[3,5-dichloro-4-(1-methyl-6-oxo-5-propan-2-ylpyridazin-3-yl)oxyphenyl]-5-oxo-4H-1,2,4-oxadiazole-3-carboxamide;
PubChem CID	146402726;
ChEMBL	ChEMBL4782668;
Chemical and physical data
Formula	C17H15Cl2N5O5
Molar mass	440.24 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CC(C)C1=CC(=NN(C1=O)C)OC2=C(C=C(C=C2Cl)NC(=O)C3=NOC(=O)N3)Cl;
	InChI InChI=1S/C17H15Cl2N5O5/c1-7(2)9-6-12(22-24(3)16(9)26)28-13-10(18)4-8(5-11(13)19)20-15(25)14-21-17(27)29-23-14/h4-7H,1-3H3,(H,20,25)(H,21,23,27); Key:WFIWVDVCNWOMQV-UHFFFAOYSA-N;

TERN-501 is a selective thyromimetic drug that is being developed for the treatment of non-alcoholic fatty liver disease.^[1]^[2]

References

This pharmacology-related article is a stub. You can help Wikipedia by expanding it.

Legal status

Legal status	Investigational
Identifiers
IUPAC name N-[3,5-dichloro-4-(1-methyl-6-oxo-5-propan-2-ylpyridazin-3-yl)oxyphenyl]-5-oxo-4H-1,2,4-oxadiazole-3-carboxamide
PubChem CID	146402726
ChEMBL	ChEMBL4782668
Chemical and physical data
Formula	C₁₇H₁₅Cl₂N₅O₅
Molar mass	440.24 g·mol⁻¹
3D model (JSmol)	Interactive image
SMILES CC(C)C1=CC(=NN(C1=O)C)OC2=C(C=C(C=C2Cl)NC(=O)C3=NOC(=O)N3)Cl
InChI InChI=1S/C17H15Cl2N5O5/c1-7(2)9-6-12(22-24(3)16(9)26)28-13-10(18)4-8(5-11(13)19)20-15(25)14-21-17(27)29-23-14/h4-7H,1-3H3,(H,20,25)(H,21,23,27) Key:WFIWVDVCNWOMQV-UHFFFAOYSA-N